MiRNA and Target Oncogene Regulation in Triple Negative Breast Cancer: An Age, Ethnic and Environmental Related Neoplastic Event
Journal Title: Journal of Cancer and Tumor International - Year 2015, Vol 2, Issue 2
Abstract
Triple-negative breast cancer is a type of aggressive breast cancer without the immunohistochemical expression of estrogen receptors, progesterone receptors and human epidermal growth factor receptor-2; with poor prognosis, greater relapse risk and worse survival in general. Its proportion in all breast cancer cases ranges from 15 to 20%. Triple negative breast cancer is more prevalent among younger women, particularly African, African-American, Latino and obese women. This observed prevalence, is an age and ethnic related factor which fingers estrogenic agents as a common feature in TNBC occurrence. Inherited variation in the let-7 binding site on the KRAS oncogene has been revealed to confer increased susceptibility to triple negative breast cancer, especially in premenopausal, African-American and Hispanic women. About 15-40% of triple negative breast tumors have BRCA-related epigenetic down-regulation and increased expression of the inhibitors of BRCA1 function, which have be found to be related to indirect regulation of ID4 oncogene by miR-342. When compared with wholesome breast tissues, miR-21, miR-210 and miR-221 expression are observed to be elevated in the triple-negative breast cancer; whereas expression of miR-10b, miR-145, miR-205, miR-122a, miR-200a/miR-200b, miR-146b and miR-148a are decreased. Interestingly, eight miRNAs are differentially expressed in metastatic breast cancer tissues (miR-200b, miR- 148a, miR-424, miR-125a-5P, miR-627, miR-579, let-7g and miR-101) when compared with the non-metastatic type. The consequence of differential miRNA expression in triple negative breast is a function of target oncogene modulation which may be related to nutritional, environmental and socio-cultural factors. Insights into the risk factors, miRNA and their validated target may provide novel diagnostic tools and treatment options for triple negative breast cancer.
Authors and Affiliations
Jude Ogechukwu Okoye, Francis Obinna Okoye
Keywords
Related Articles
- EP ID EP242946
- DOI 10.9734/JCTI/2015/18131
- Views 128
- Downloads 0
Myofibroblastoma of Axillary Soft Tissue in a Child
Aims: Myofibroblastoma (MFB) is an unusual benign mesenchymal tumour which has neoplastic cells showing a variable myofibroblastic differentiation at morphologic, immunohistochemical and ultrastructural levels. MFB is co...
Chemotherapy Induced Skin Toxicities and Review of Literature
Chemotherapeutic drugs have proven efficacy in the treatment of most of the cancers. Chemotherapy induced side effects are commonly seen in clinical oncology. Development of new chemotherapeutic drugs and various new pro...
Evaluation of Cardiac Biomarkers in Detection of Cardiomyopathy Induced by Cardiotoxic Chemotherapeutic Agents
Background: Doxorubicin is a potent chemotherapeutic drug. The clinical usefulness of doxorubicin has been limited largely by the risk of cardiomyopathy and life-threatening heart failure. Therefore early identification...
Role of Breast Feeding and Parity in Prevalence of Breast Cancer and Bone Metastasis
Our aim was to evaluate the role of breast feeding and parity (alive and abortion) in prevalence of breast cancer and secondary bone metastasis. For The study purpose 100 diagnosed females of breast cancer were selected....
Occurrence of Factors Influencing Recurrence and/or Metastasis in Dermatofibrosarcoma Protuberans
Introduction: Dermatofibrosarcoma protuberans (DFSP) is a slow growing tumour with limited metastatic potential. However it acquires aggressive attributes as it enlarges or if it recurs following excision. The fibrosarco...